Hammer L, Levin-Salomon V, Yaeli-Slonim N, Weiss M, Dekel-Bird N, Olender T
Mol Oncol. 2022; 16(6):1365-1383.
PMID: 35122388
PMC: 8936513.
DOI: 10.1002/1878-0261.13187.
Alhebshi H, Tian K, Patnaik L, Taylor R, Bezecny P, Hall C
Int J Mol Sci. 2021; 22(24).
PMID: 34947995
PMC: 8707832.
DOI: 10.3390/ijms222413198.
Noguchi R, Yamaguchi K, Ikenoue T, Terakado Y, Ohta Y, Yamashita N
Oncol Lett. 2017; 14(1):877-884.
PMID: 28693246
PMC: 5494721.
DOI: 10.3892/ol.2017.6224.
Pfister N, Prives C
Cold Spring Harb Perspect Med. 2016; 7(2).
PMID: 27836911
PMC: 5287061.
DOI: 10.1101/cshperspect.a026054.
Hainaut P, Pfeifer G
Cold Spring Harb Perspect Med. 2016; 6(11).
PMID: 27503997
PMC: 5088513.
DOI: 10.1101/cshperspect.a026179.
Genetic Instability and Disease Prognostication.
Gemoll T, Auer G, Ried T, Habermann J
Recent Results Cancer Res. 2015; 200:81-94.
PMID: 26376873
PMC: 7737009.
DOI: 10.1007/978-3-319-20291-4_4.
p53 mutations in classic and pleomorphic invasive lobular carcinoma of the breast.
Ercan C, van Diest P, van der Ende B, Hinrichs J, Bult P, Buerger H
Cell Oncol (Dordr). 2012; 35(2):111-8.
PMID: 22354696
PMC: 3306558.
DOI: 10.1007/s13402-012-0071-y.
A Cohort Study of p53 Mutations and Protein Accumulation in Benign Breast Tissue and Subsequent Breast Cancer Risk.
Kabat G, Kandel R, Glass A, Jones J, Olson N, Duggan C
J Oncol. 2011; 2011:970804.
PMID: 21869889
PMC: 3160103.
DOI: 10.1155/2011/970804.
Immunohistochemical detection of p53 protein in basal cell skin cancer after microwave-assisted antigen retrieval.
Evke E, Minbay F, Temel S, Kahveci Z
J Mol Histol. 2008; 40(1):13-21.
PMID: 19096907
DOI: 10.1007/s10735-008-9208-8.
Biological indices in the assessment of breast cancer.
Leong A, Lee A
Clin Mol Pathol. 1995; 48(5):M221-38.
PMID: 16696013
PMC: 407976.
DOI: 10.1136/mp.48.5.m221.
Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines.
Liu Y, Bodmer W
Proc Natl Acad Sci U S A. 2006; 103(4):976-81.
PMID: 16418264
PMC: 1327731.
DOI: 10.1073/pnas.0510146103.
The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status.
Kostler W, Brodowicz T, Hudelist G, Rudas M, Horvat R, Steger G
J Cancer Res Clin Oncol. 2005; 131(7):420-8.
PMID: 15864644
DOI: 10.1007/s00432-005-0670-3.
Biological features of premalignant disease in the human breast.
Allred D, Mohsin S
J Mammary Gland Biol Neoplasia. 2004; 5(4):351-64.
PMID: 14973381
DOI: 10.1023/a:1009573710675.
Prognostic implications of p53 and bcl-2 expression in 108 women with stage two breast cancer.
McLaughlin R, OHanlon D, McHale T, Connolly C, Given H
Ir J Med Sci. 2001; 170(1):11-3.
PMID: 11440404
DOI: 10.1007/BF03167712.
Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53.
Beenken S, Grizzle W, Crowe D, Conner M, Weiss H, Sellers M
Ann Surg. 2001; 233(5):630-8.
PMID: 11323501
PMC: 1421302.
DOI: 10.1097/00000658-200105000-00006.
A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain.
Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C
Mol Cell Biol. 2001; 21(5):1874-87.
PMID: 11238924
PMC: 86759.
DOI: 10.1128/MCB.21.5.1874-1887.2001.
Role of p53 assessment in management of Barrett's esophagus.
Kubba A, Poole N, Watson A
Dig Dis Sci. 1999; 44(4):659-67.
PMID: 10219819
DOI: 10.1023/a:1026608319881.
Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis.
Abdel-Fattah R, Challen C, Griffiths T, Robinson M, Neal D, Lunec J
Br J Cancer. 1998; 77(12):2230-8.
PMID: 9649138
PMC: 2150401.
DOI: 10.1038/bjc.1998.371.
Prognostic value of immunohistochemistry for p53 in primary soft-tissue sarcomas: a multivariate analysis of five antibodies.
Wurl P, Taubert H, Meye A, Berger D, Lautenschlager C, Holzhausen H
J Cancer Res Clin Oncol. 1997; 123(9):502-8.
PMID: 9341900
DOI: 10.1007/BF01192205.
Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer.
Niskanen E, Blomqvist C, Franssila K, Hietanen P, Wasenius V
Br J Cancer. 1997; 76(7):917-22.
PMID: 9328152
PMC: 2228069.
DOI: 10.1038/bjc.1997.484.